Section 5 of 6
Economic information and modeling report
2 evidence topics · 2 sources
Modeling overview
Summary
The verified economic result concerns avapritinib plus best supportive care versus best supportive care alone: the Canadian recommendation reports an ICER of $1,871,956 per QALY gained. This is comparator cost-effectiveness evidence, not a bezuclastinib budget impact estimate. No bezuclastinib-specific price or eligible budget impact model is included in the report, so comparator estimates cannot populate the product-specific model.
Canadian reimbursement recommendation: avapritinib plus BSC versus BSC alone, base-case ICER
Bezuclastinib-specific price, cost-effectiveness analysis, and budget-impact model
No evidence found.
Budget impact model
Approach and framework
Bezuclastinib-specific models
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.